CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02257528
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:21.045120+00:00
Published At: 2020-08-12T00:00:00+00:00
Record Updated At: 2025-09-08
Results Posted At: 2020-08-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Recurrent Cervical Carcinoma", "Stage IV Cervical Cancer AJCC v6 and v7", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVB Cervical Cancer AJCC v6 and v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-08"
protocolSection.identificationModule.nctId: "NCT02257528"
protocolSection.identificationModule.officialTitle: "A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-08-12"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.